国际肿瘤学杂志
國際腫瘤學雜誌
국제종류학잡지
JOURNAL OF INTERNATIONAL ONCOLOGY
2015年
4期
241-244
,共4页
冷政伟%杨刚%李勇%石刚
冷政偉%楊剛%李勇%石剛
랭정위%양강%리용%석강
肝肿瘤%肿瘤干细胞%信号传导%细胞球
肝腫瘤%腫瘤榦細胞%信號傳導%細胞毬
간종류%종류간세포%신호전도%세포구
Liver neoplasms%Neoplastic stem cells%Signal transduction%Spheroid cells
目的:探讨 LY294002对富集肝癌干细胞的细胞球增殖和磷脂酰肌醇3-激酶-蛋白激酶 B (PI3K-Akt)通路的影响。方法对人肝癌 HepG2细胞进行无血清悬浮培养获得富集肝癌干细胞的细胞球,消化后使用 LY294002(10、20、30μmol/ L)培养作为实验组,对照组不使用 LY294002。细胞活性计数法检测细胞增殖活性,Western blotting 检测 Akt,实时定量 PCR 检测 PI3K-Akt 信号通路下游基因诱骗受体3(DcR3)、哺乳动物雷帕霉素靶蛋白(mTOR)、B 淋巴细胞瘤-2(Bcl-2)、细胞周期蛋白 D1(Cyclin D1)的表达。结果与对照组相比,30μmol/ L LY294002可显著抑制富集肝癌干细胞的细胞球增殖,吸光度(A)值有显著差异[(0.14±0.03):(0.56±0.01),t =-8.915,P =0.000];磷酸化 Akt 表达水平明显降低[(0.57±0.08):(0.16±0.42),t =6.027,P =0.026];DcR3[(0.38±0.08):1,t =13.060, P =0.006]、mTOR[(0.37±0.04):1,t =30.363,P =0.001]、Bcl-2[(0.26±0.04):1,t =33.554,P =0.001]、Cyclin D1[(0.1±0.02):1,t =63.528,P =0.000]表达明显减少。结论 LY294002可能通过抑制 PI3K-Akt 通路而抑制富集人肝癌干细胞的细胞球的增殖。
目的:探討 LY294002對富集肝癌榦細胞的細胞毬增殖和燐脂酰肌醇3-激酶-蛋白激酶 B (PI3K-Akt)通路的影響。方法對人肝癌 HepG2細胞進行無血清懸浮培養穫得富集肝癌榦細胞的細胞毬,消化後使用 LY294002(10、20、30μmol/ L)培養作為實驗組,對照組不使用 LY294002。細胞活性計數法檢測細胞增殖活性,Western blotting 檢測 Akt,實時定量 PCR 檢測 PI3K-Akt 信號通路下遊基因誘騙受體3(DcR3)、哺乳動物雷帕黴素靶蛋白(mTOR)、B 淋巴細胞瘤-2(Bcl-2)、細胞週期蛋白 D1(Cyclin D1)的錶達。結果與對照組相比,30μmol/ L LY294002可顯著抑製富集肝癌榦細胞的細胞毬增殖,吸光度(A)值有顯著差異[(0.14±0.03):(0.56±0.01),t =-8.915,P =0.000];燐痠化 Akt 錶達水平明顯降低[(0.57±0.08):(0.16±0.42),t =6.027,P =0.026];DcR3[(0.38±0.08):1,t =13.060, P =0.006]、mTOR[(0.37±0.04):1,t =30.363,P =0.001]、Bcl-2[(0.26±0.04):1,t =33.554,P =0.001]、Cyclin D1[(0.1±0.02):1,t =63.528,P =0.000]錶達明顯減少。結論 LY294002可能通過抑製 PI3K-Akt 通路而抑製富集人肝癌榦細胞的細胞毬的增殖。
목적:탐토 LY294002대부집간암간세포적세포구증식화린지선기순3-격매-단백격매 B (PI3K-Akt)통로적영향。방법대인간암 HepG2세포진행무혈청현부배양획득부집간암간세포적세포구,소화후사용 LY294002(10、20、30μmol/ L)배양작위실험조,대조조불사용 LY294002。세포활성계수법검측세포증식활성,Western blotting 검측 Akt,실시정량 PCR 검측 PI3K-Akt 신호통로하유기인유편수체3(DcR3)、포유동물뢰파매소파단백(mTOR)、B 림파세포류-2(Bcl-2)、세포주기단백 D1(Cyclin D1)적표체。결과여대조조상비,30μmol/ L LY294002가현저억제부집간암간세포적세포구증식,흡광도(A)치유현저차이[(0.14±0.03):(0.56±0.01),t =-8.915,P =0.000];린산화 Akt 표체수평명현강저[(0.57±0.08):(0.16±0.42),t =6.027,P =0.026];DcR3[(0.38±0.08):1,t =13.060, P =0.006]、mTOR[(0.37±0.04):1,t =30.363,P =0.001]、Bcl-2[(0.26±0.04):1,t =33.554,P =0.001]、Cyclin D1[(0.1±0.02):1,t =63.528,P =0.000]표체명현감소。결론 LY294002가능통과억제 PI3K-Akt 통로이억제부집인간암간세포적세포구적증식。
Objective To investigate the impact of LY294002 on the proliferation of cancer stem cell-enriched spheroid cells from human hepatocellular carcinoma via regulating phosphatidylinositol-3-kinaseprotein kinase B(PI3K-Akt)signaling pathway. Methods The cancer stem cell-enriched spheroid cells were genera-ted by culturing HepG2 cells in serum-free medium. LY294002(10,20,30 μmol/ L),an inhibitor of PI3K-Akt signaling pathway,was used in the experimental groups,without used in the control group. The impact of LY294002 on the spheroid cells proliferation was confirmed by cell counting kit(CCK-8 kit). The expression of Akt was tested by Western blotting. The expression of PI3K-Akt signaling pathway downstream genes such as decoy receptor 3(DcR3),mammalian target of rapamycin(mTOR),B-cell lymphoma(Bcl)-2 and Cyclin D1 were tested by real-time PCR. Results 30 μmol/ L LY294002 could inhibit the proliferation of spheroid cells, and significant difference in the absorbance(A value)was observed between the experimental group and control group[(0. 14 ± 0. 03)vs(0. 56 ± 0. 01),t = - 8. 915,P = 0. 000]. The expression level of phosphorylated Akt protein increased[(0. 57 ± 0. 08)vs(0. 16 ± 0. 42),t = 6. 027,P = 0. 026]. The mRNA of DcR3 [(0. 38 ± 0. 08)vs 1,t = 13. 060,P = 0. 006],mTOR[(0. 37 ± 0. 04)vs 1,t = 30. 363,P = 0. 001],Bcl-2 [(0. 26 ± 0. 04)vs 1,t = 33. 554,P = 0. 001]and Cyclin D1[(0. 10 ± 0. 02)vs 1,t = 63. 528,P = 0. 000] decreased. Conclusion LY294002 could inhibit the proliferation of cancer stem cell-enriched spheroid cells from human hepatocellular carcinoma via inhibiting PI3K-Akt signaling pathway.